Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Buy" by Brokerages

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) has been assigned a consensus recommendation of "Buy" from the five research firms that are covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $30.00.

A number of equities research analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $33.00 price objective on shares of Cullinan Therapeutics in a research note on Wednesday, April 16th. Morgan Stanley restated an "overweight" rating and set a $35.00 price objective (down from $38.00) on shares of Cullinan Therapeutics in a research note on Friday, March 7th. UBS Group cut their price objective on shares of Cullinan Therapeutics from $30.00 to $24.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Finally, Stifel Nicolaus started coverage on shares of Cullinan Therapeutics in a research report on Wednesday. They issued a "buy" rating and a $22.00 price target on the stock.

Institutional Trading of Cullinan Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Deerfield Management Company L.P. Series C grew its position in Cullinan Therapeutics by 3.0% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 3,379,399 shares of the company's stock valued at $41,161,000 after acquiring an additional 99,399 shares during the period. Vanguard Group Inc. grew its position in Cullinan Therapeutics by 3.5% in the first quarter. Vanguard Group Inc. now owns 3,039,731 shares of the company's stock valued at $23,011,000 after acquiring an additional 103,504 shares during the period. Blue Owl Capital Holdings LP grew its position in Cullinan Therapeutics by 17.9% in the fourth quarter. Blue Owl Capital Holdings LP now owns 2,370,972 shares of the company's stock valued at $28,878,000 after acquiring an additional 360,000 shares during the period. Franklin Resources Inc. grew its position in Cullinan Therapeutics by 0.4% in the fourth quarter. Franklin Resources Inc. now owns 2,199,709 shares of the company's stock valued at $26,792,000 after acquiring an additional 8,447 shares during the period. Finally, Alliancebernstein L.P. grew its position in Cullinan Therapeutics by 8.5% in the fourth quarter. Alliancebernstein L.P. now owns 2,011,525 shares of the company's stock valued at $24,500,000 after acquiring an additional 157,115 shares during the period. 86.31% of the stock is currently owned by institutional investors.

Cullinan Therapeutics Trading Down 3.8%

CGEM stock opened at $8.61 on Friday. Cullinan Therapeutics has a twelve month low of $6.85 and a twelve month high of $21.82. The company has a market capitalization of $508.12 million, a P/E ratio of -3.03 and a beta of -0.04. The firm has a 50 day simple moving average of $8.10 and a 200-day simple moving average of $9.49.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.74) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.04. On average, research analysts predict that Cullinan Therapeutics will post -3.04 EPS for the current year.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.